Physician profile
Luis R Ambert
NPI 1295794014
$64,498.60
in general payments reported to CMS, 2019-2025
22 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $296 · 2021: $457 · 2022: $822 · 2023: $12K · 2024: $25K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $12K · Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,000.00 |
| Consulting Fee | $12,000.00 |
| Food and Beverage | $1,351.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $60,000.00 | 2023-2025 | Trelstar |
| Boston Scientific Corporation | $1,165.23 | 2019-2025 | Ams 700 Cxr Rte Kit, Ams 700 |
| Medtronic, INC. | $690.33 | 2019-2025 | Interstim |
| Travere Therapeutics, INC. | $366.40 | 2019-2021 | |
| Becton, Dickinson and Company | $358.45 | 2023-2025 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, Proxis Ureteral Access Sheath, Aptra |
| Merck Sharp & Dohme LLC | $224.26 | 2019-2022 | |
| Teleflex LLC | $223.72 | 2022-2024 | Urolift |
| Neotract INC. | $198.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $197.73 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $187.96 | 2019-2024 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $123.55 | 2025 | |
| Janssen Biotech, INC. | $123.00 | 2019-2020 | |
| Axonics, INC. | $121.37 | 2021 | |
| Urogen Pharma, INC. | $114.14 | 2022 | |
| Olympus Latin America, INC. | $100.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $85.16 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $64.41 | 2019 | |
| Abbvie INC. | $50.00 | 2022-2024 | |
| Pbg Puerto Rico LLC | $49.05 | 2019-2020 | |
| Pfizer Pharmaceuticals LLC | $24.44 | 2019 | |
| Tolmar, INC. | $18.75 | 2024 | |
| Pharmaand Gmbh | $11.76 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.